The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element
Open accessAbstract
In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell’s transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase–binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ability of AlphaGenome to simultaneously score variant effects across all modalities accurately recapitulates the mechanisms of clinically relevant variants near the TAL1 oncogene6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Detailed ALT–REF predictions for an oncogenic insertion (chr. 1: 47239296: C>ACG) characterized in ref. 6. Shown are differences between AlphaGenome predictions between the ALT and REF sequences of the variant in CD34+ CMP tracks. The ALT sequence increases expression of the TAL1 gene 7.5 kb away.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We evaluated three groups of gain-of-function mutations affecting the TAL1 gene in T cell acute lymphoblastic leukaemia (T-ALL): a cluster of 5′ neo-enhancer mutations upstream of the TAL1 TSS6,33, an intronic single-nucleotide variant (SNV)34 and a 3′ neo-enhancer35.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, the alternative sequence introduced a MYB motif at the variant position predicted to increase TAL1 expression, chromatin accessibility and H3K27ac chromatin marks (Fig. 6e), as discovered previously6.”
From Advancing regulatory variant effect prediction with AlphaGenome (2026) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Histone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
Self-citationSelective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Self-citation
Cited by
Sorted by citations
Items 201–300 of 805
Yusenko, M. V., Trentmann, A., Andersson, M. K., Ghani, L. A., Jakobs, A., Arteaga, M. F., Mikesch, J., von Kries, J. P., Stenman, G., & Klempnauer, K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.039 · Cited by 64
The Emerging Role of Super-enhancers as Therapeutic Targets in The Digestive System Tumors
Li, X., Qu, J., Teng, X.-Q., Zhuang, H.-H., Dai, Y.-H., Yang, Z. G., & Qu, Q. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78535 · Cited by 65
Takao, S., Forbes, L., Uni, M., Cheng, S., Pineda, J. M. B., Tarumoto, Y., Cifani, P., Minuesa, G., Chen, C. Y., Kharas, M. G., et al. (2021) · eLife · doi:10.7554/elife.65905 · Cited by 62
Implications of Enhancer Transcription and eRNAs in Cancer
Adhikary, S., Roy, S., Chacon, J. A., Gadad, S. S., & Das, C. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4010 · Cited by 64
Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
Feigin, M. E., Garvin, T. H., Bailey, P. J., Waddell, N., Chang, D. K.-F., Kelley, D. R., Shuai, S., Gallinger, S., McPherson, J. D., Grimmond, S. M., et al. (2017) · Nature Genetics · doi:10.1038/ng.3861 · Cited by 64
Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia
Tan, S. H., Bertulfo, F. C., & Sanda, T. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00218 · Cited by 61
Self-citationTAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia
Sanda, T., & Leong, W. Z. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.06.001 · Cited by 62
Self-citationSmall-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells
Uttarkar, S., Piontek, T., Dukare, S., Schomburg, C., Schlenke, P., Berdel, W. E., Müller‐Tidow, C., Schmidt, T. J., & Klempnauer, K. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0185 · Cited by 60
Bojcsuk, D., Nagy, G., & Bálint, B. L. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1283 · Cited by 63
Molecular markers in ALL: Clinical implications
Kimura, S., & Mullighan, C. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101193 · Cited by 63
Combined burden and functional impact tests for cancer driver discovery using DriverPower
Shuai, S., PCAWG Drivers and Functional Interpretation Working Group, Abascal, F., Amin, S. B., Bader, G. D., Bandopadhayay, P., Barenboim, J., Beroukhim, R., Bertl, J., Boroevich, K. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-13929-1 · Cited by 60
Li, K., Zhang, Y., Liu, X., Liu, Y., Gu, Z., Cao, H., Dickerson, K. E., Chen, M., Chen, W., Shao, Z., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1128 · Cited by 61
Eliades, P. J., Abraham, B. J., Ji, Z., Miller, D. M., Christensen, C. L., Kwiatkowski, N. P., Kumar, R., Njauw, C.-N. J., Taylor, M., Miao, B., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.056 · Cited by 60
Self-citationFrazer, C., Staples, M. I., Kim, Y., Hirakawa, M., Dowell, M. A., Johnson, N. V., Hernday, A. D., Ryan, V. H., Fawzi, N. L., Finkelstein, I. J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0760-7 · Cited by 56
Classification and risk stratification in T-lineage acute lymphoblastic leukemia
Pölönen, P., Mullighan, C. G., & Teachey, D. T. (2024) · Blood · doi:10.1182/blood.2023022920 · Cited by 56
Epigenetic determinants of metastasis
Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 58
Tsuchiya, H., Ota, M., Sumitomo, S., Ishigaki, K., Suzuki, A., Sakata, T., Tsuchida, Y., Inui, H., Hirose, J., Kochi, Y., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218189 · Cited by 58
ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer
Pozo, K., Kollipara, R. K., Kelenis, D. P., Rodarte, K. E., Ullrich, M. S., Zhang, X., Minna, J. D., & Johnson, J. E. B. (2021) · iScience · doi:10.1016/j.isci.2021.102953 · Cited by 58
NF-κB–Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis
Rodrigues, P., Patel, S. A., Harewood, L., Olan, I., Vojtasova, E., Syafruddin, S. E., Zaini, M. N., Richardson, E. K., Burge, J., Warren, A. Y., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1211 · Cited by 56
Gao, R., Cao, C., Zhang, M., Lopez, M.-C., Yan, Y., Chen, Z., Mitani, Y., Zhang, L., Zajac‐Kaye, M., Liu, B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2985 · Cited by 52
Targeting the transcription factor Myb by small-molecule inhibitors
Uttarkar, S., Frampton, J., & Klempnauer, K. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.12.003 · Cited by 52
Qian, M., Zhao, X., Devidas, M., Yang, W., Gocho, Y., Smith, C. J., Gastier, J. M., Li, Y., Xu, H. Y., Zhang, S., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz043 · Cited by 53
Self-citationDeregulated Regulators: Disease-Causing cis Variants in Transcription Factor Genes
van der Lee, R., Correard, S., & Wasserman, W. W. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.04.006 · Cited by 53
Zheng, C., Liu, M., Ge, Y., Qian, Y., & Fan, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04563-9 · Cited by 50
Lingering Questions about Enhancer RNA and Enhancer Transcription-Coupled Genomic Instability
Rothschild, G., & Basu, U. (2017) · Trends in Genetics · doi:10.1016/j.tig.2016.12.002 · Cited by 52
OncoBase: a platform for decoding regulatory somatic mutations in human cancers
Li, X., Shi, L., Wang, Y., Zhong, J., Zhao, X., Teng, H., Shi, X., Yang, H., Ruan, S., Li, M., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1139 · Cited by 49
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Comparative analyses of super-enhancers reveal conserved elements in vertebrate genomesPreprint
Perez-Rico, Y. A., Boeva, V., Mallory, A. C., Bitetti, A., Majello, S., Barillot, E., & Shkumatava, A. (2016) · Genome Research · doi:10.1101/gr.203679.115 · Cited by 51
Emerging Implications of Phase Separation in Cancer
Ren, J., Zhang, Z., Zong, Z., Zhang, L., & Zhou, F. (2022) · Advanced Science · doi:10.1002/advs.202202855 · Cited by 48
Super-enhancers complexes zoom in transcription in cancer
Wang, M., Chen, Q., Wang, S., Xie, H., Liu, J., Huang, R., Xiang, Y., Jiang, Y., Tian, D., & Bian, E. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02763-5 · Cited by 51
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9
Cheung, A. H. K., Chow, C., Zhang, J., Zhou, Y., Huang, T., Ng, K. C.-K., Or, T. C. T., Yao, Y. Y., Dong, Y., Fung, J. M.-W., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0056-1 · Cited by 50
Tarczewska, A., & Greb‐Markiewicz, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215306 · Cited by 49
Transcriptionally active enhancers in human cancer cells
Lidschreiber, K., Jung, L. A., von der Emde, H., Dave, K., Taipale, J., Cramer, P., & Lidschreiber, M. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209873 · Cited by 49
Nameki, R. A., Chang, H. S. Y., Reddy, J., Corona, R. I., & Lawrenson, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107722 · Cited by 48
Zhou, R. W., Xu, J., Martin, T. C., Zachem, A. L., He, C., Ozturk, S., Demircioğlu, D., Bansal, A., Trotta, A. P., Giotti, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33377-8 · Cited by 49
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 52
Reassessing the Potential of Myb-targeted Anti-cancer Therapy
Liu, X., Xu, Y., Han, L., & Yi, Y. (2018) · Journal of Cancer · doi:10.7150/jca.23992 · Cited by 47
Resolving mechanisms of immune‐mediated disease in primary CD4 T cells
Bourges, C., Groff, A. F., Burren, O. S., Gerhardinger, C., Mattioli, K., Hutchinson, A., Hu, T. X., Anand, T., Epping, M. W., Wallace, C., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012112 · Cited by 45
Guo, L., Li, J., Zeng, H., Guzman, A. G., Li, T., Lee, M., Zhou, Y., Goodell, M. A., STEPHAN, C. C., Davies, P. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14604-6 · Cited by 47
Laukkanen, S., Veloso, A. B., Yan, C., Oksa, L., Alpert, E. J., Do, D., Hyvärinen, N., McCarthy, K. M., Adhikari, A., Yang, Q., et al. (2022) · Blood · doi:10.1182/blood.2021015106 · Cited by 46
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Yang, J., Zhou, F., Luo, X., Fang, Y., Wang, X., Liu, X., Xiao, R., Jiang, D., Tang, Y., Yang, G., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02366-3 · Cited by 56
Hu, S., Qian, M., Zhang, H., Guo, Y. A., Yang, J., Zhao, X., He, H., Lu, J., Pan, J., Chang, M., et al. (2017) · Blood · doi:10.1182/blood-2017-03-771162 · Cited by 46
Liau, W., Tan, S. H., Ngoc, P. C. T., Wang, C. Q., Tergaonkar, V., Feng, H., Gong, Z., Osato, M., Look, A. T., & Sanda, T. (2016) · Leukemia · doi:10.1038/leu.2016.392 · Cited by 47
Self-citationEnhancer dysfunction in leukemia
Bhagwat, A. S., Lu, B., & Vakoc, C. R. (2018) · Blood · doi:10.1182/blood-2017-11-737379 · Cited by 45
Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia
Ngoc, P. C. T., Tan, S. H., Tan, T. K., Chan, M. M., Li, Z., Yeoh, A. E. J., Tenen, D. G., & Sanda, T. (2018) · Leukemia · doi:10.1038/s41375-018-0110-4 · Cited by 45
Self-citationAndersson, M. K., Åman, P., & Stenman, G. (2019) · Cells · doi:10.3390/cells8080913 · Cited by 45
Touzart, A., Mayakonda, A., Smith, C. L., Hey, J., Tóth, R., Cieślak, A., Andrieu, G. P., Quang, C. T., Latiri, M., Ghysdael, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc4834 · Cited by 43
Enhancer RNAs: a missing regulatory layer in gene transcription
Mao, R., Wu, Y., Ming, Y., Xu, Y., Wang, S., Chen, X., Wang, X., & Fan, Y. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9370-9 · Cited by 42
Liang, H.-C., Costanza, M., Prutsch, N., Zimmerman, M. W., Gurnhofer, E., Montes-Mojarro, I. A., Abraham, B. J., Prokoph, N., Stoiber, S., Tangermann, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25379-9 · Cited by 43
Self-citationAntoniani, C., Romano, O., & Miccio, A. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0192 · Cited by 50
Brachyury, Foxa2 and the cis-Regulatory Origins of the Notochord
José‐Edwards, D. S., Oda‐Ishii, I., Kugler, J. E., Passamaneck, Y. J., Katikala, L., Nibu, Y., & Gregorio, A. D. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005730 · Cited by 41
Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia
Tan, T. K., Zhang, C., & Sanda, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2518-z · Cited by 42
Self-citationWalavalkar, K., Saravanan, B., Singh, A. K., Jayani, R. S., Nair, A., Farooq, U., Islam, Z., Soota, D., Mann, R., Shivaprasad, P. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17325-y · Cited by 42
Cui, S., Wu, Q., Liu, M., Su, M., Liu, S., Shao, L., Han, X., & He, H. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03538-6 · Cited by 42
Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia
Smeenk, L., Ottema, S., Mulet‐Lazaro, R., Ebert, A., Havermans, M., Varea, A. A., Fellner, M., Pastoors, D., van Herk, S., Erpelinck-Verschueren, C. A. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1793 · Cited by 41
CCNB1 Expedites the Progression of Cervical Squamous Cell Carcinoma via the Regulation by FOXM1
Li, S., Liu, N., Piao, J., Meng, F., & Li, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s279951 · Cited by 41
RetractedExploiting Epigenetic Alterations in Prostate Cancer
Baumgart, S. J., & Haendler, B. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18051017 · Cited by 44
Huang, M., Chen, Y., Yang, M., Guo, A., Xu, Y., Xu, L., & Koeffler, H. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx796 · Cited by 41
Hemming, M. L., Lawlor, M. A., Zeid, R., Lesluyes, T., Fletcher, J. A., Raut, C. P., Sicińska, E., Chibon, F., Armstrong, S. A., Demetri, G. D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802079115 · Cited by 39
Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation
Gachet, S., El-Chaar, T., Avran, D., Genescà, E., Catez, F., Quentin, S., Delord, M., Thérizols, G., Briot, D., Meunier, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0831 · Cited by 46
Wandler, A. M., Huang, B. J., Craig, J. W., Hayes, K., Yan, H. H., Meyer, L. K., Scacchetti, A., Monsalve, G. C., Dail, M., Li, Q., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0748-6 · Cited by 43
Meng, J., Han, J., Wang, X., Wu, T., Zhang, H., An, H., Qin, L., Sun, Y., Zhong, W., Yang, C., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106661 · Cited by 42
Galvan, M. L., Paradise, C. R., Kubrova, E., Jerez, S., Khani, F., Thaler, R., Dudakovic, A., & van Wijnen, A. J. (2021) · Bone · doi:10.1016/j.bone.2021.115993 · Cited by 40
Oncogenic seRNA functional activation: a novel mechanism of tumorigenesis
Tan, Y., Li, Y., & Tang, F. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01195-5 · Cited by 39
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 38
Dynamics of chromatin accessibility and epigenetic state in response to UV damage
Schick, S., Fournier, D., Thakurela, S., Sahu, S. K., Garding, A., & Tiwari, V. K. (2015) · Journal of Cell Science · doi:10.1242/jcs.173633 · Cited by 42
Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells
Zha, L., Cao, Q., Cui, X., Li, F., Liang, H., Xue, B., & Shi, H. (2016) · Medical Oncology · doi:10.1007/s12032-016-0734-z · Cited by 39
Nayak, S., Aich, M., Kumar, A., Sengupta, S., Bajad, P., Dhapola, P., Paul, D., Narta, K., Purkrait, S., Mehani, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26000-8 · Cited by 39
León, T. E., Rapoz-D’Silva, T., Bertoli, C., Rahman, S., Magnussen, M., Philip, B., Farah, N., Richardson, S. E., Ahrabi, S., Guerra‐Assunção, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0789 · Cited by 39
Self-citationTranscriptional dysregulation by aberrant enhancer activation and rewiring in cancer
Okabe, A., & Kaneda, A. (2021) · Cancer Science · doi:10.1111/cas.14884 · Cited by 41
An oncogenic enhancer encodes selective selenium dependency in AML
Eagle, K., Jiang, Y., Shi, X. E., Li, M., Obholzer, N. D., Hu, T., Perez, M. W., Koren, J. V., Kitano, A., Yi, J. S., et al. (2022) · Cell stem cell · doi:10.1016/j.stem.2022.01.003 · Cited by 40
Chen, P. B., Fiaux, P. C., Zhang, K., Li, B., Kubo, N., Jiang, S., Hu, R., Rooholfada, E., Wu, S., Wang, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111630 · Cited by 41
Beyond the exome: the role of non-coding somatic mutations in cancer
Piraino, S. W., & Furney, S. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv561 · Cited by 39
Liang, Y. J., Xu, P., Zou, Q., Luo, H., & Yu, W. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.004 · Cited by 37
Franciosa, G., Smits, J. G. A., Minuzzo, S. A., Martínez‐Val, A., Indraccolo, S., & Olsen, J. V. (2021) · Nature Communications · doi:10.1038/s41467-021-22787-9 · Cited by 37
Biomolecular condensates in cancer biology
Suzuki, H. I., & Onimaru, K. (2021) · Cancer Science · doi:10.1111/cas.15232 · Cited by 37
Fuglerud, B. M., Lemma, R. B., Wanichawan, P., Sundaram, A. Y. M., Eskeland, R., & Gabrielsen, O. S. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx364 · Cited by 36
Lopes, R., Sprouffske, K., Sheng, C., Uijttewaal, E., Wesdorp, A. E., Dahinden, J., Wengert, S., Díaz-Miyar, J., Yildiz, U., Bleu, M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf5733 · Cited by 31
Epigenetic plasticity of enhancers in cancer
Yao, J., Chen, J., Li, L., & Wu, M. (2020) · Transcription · doi:10.1080/21541264.2020.1713682 · Cited by 38
Yu, D., Yang, X. N., Lin, J., Cao, Z., Lu, C., Yang, Z., Zheng, M., Pan, R., & Cai, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724655 · Cited by 38
Chromatin modules and their implication in genomic organization and gene regulation
van Mierlo, G., Pushkarev, O., Kribelbauer, J. F., & Deplancke, B. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.11.003 · Cited by 35
Wang, J., Dayem Ullah, A. Z., & Chelala, C. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky057 · Cited by 35
Functional interrogation of non-coding DNA through CRISPR genome editing
Canver, M. C., Bauer, D. E., & Orkin, S. H. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.008 · Cited by 36
Terranova, C. J., Tang, M., Orouji, E., Maitituoheti, M., Raman, A. T., Amin, S. B., Liu, Z., & Rai, K. (2018) · Journal of Visualized Experiments · doi:10.3791/56972 · Cited by 38
Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity
Fagnocchi, L., Poli, V., & Zippo, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2820-1 · Cited by 38
Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint
Zhou, X., Wang, J., Patel, J. N., Valentine, M. B., Shao, Y., Newman, S., Sioson, E., Tian, L., Liu, Y., Brady, S. W., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.011 · Cited by 34
Superenhancer activation of KLHDC8A drives glioma ciliation and hedgehog signaling
Lee, D., Gimple, R. C., Wu, X., Prager, B. C., Qiu, Z., Wu, Q., Daggubati, V., Mariappan, A., Gopalakrishnan, J., Sarkisian, M. R., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci163592 · Cited by 36
Developmental origins shape the paediatric cancer genome
Chen, X., Yang, W., Roberts, C. W. M., & Zhang, J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00684-9 · Cited by 49
Fuglerud, B. M., Ledsaak, M., Rogne, M., Eskeland, R., & Gabrielsen, O. S. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0208-y · Cited by 31
Rodríguez-Caparrós, A., García, V., Casal, Á., López-Ros, J., Mariscal, A. G., Tani‐ichi, S., Ikuta, K., & Hernández-Munaín, C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801650 · Cited by 34
Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors
Wang, C., Zhang, L., Ke, L., Ding, W., Jiang, S., Li, D., Narita, Y., Hou, I., Liang, J., Li, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20136-w · Cited by 35
Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemiaPreprint
Teppo, S., Laukkanen, S., Liuksiala, T., Nordlund, J., Oittinen, M., Teittinen, K. J., Grönroos, T., St-Onge, P., Sinnett, D., Syvänen, A., et al. (2016) · Genome Research · doi:10.1101/gr.193649.115 · Cited by 34
Bornschein, S., Demeyer, S., Stirparo, R., Gielen, O., Vicente, C., Geerdens, E., Ghesquière, B., Aerts, S., Cools, J., & de Bock, C. E. (2017) · Leukemia · doi:10.1038/leu.2017.328 · Cited by 34
Integrative modeling reveals key chromatin and sequence signatures predicting super-enhancers
Khan, A., & Zhang, X. (2019) · Scientific Reports · doi:10.1038/s41598-019-38979-9 · Cited by 33
The Number of Transcription Factors at an Enhancer Determines Switch-like Gene Expression
Michida, H., Imoto, H., Shinohara, H., Yumoto, N., Seki, M., Umeda, M., Hayashi, T., Nikaido, I., Kasukawa, T., Suzuki, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107724 · Cited by 35
Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells
Lv, J., Zhou, Y., Zhou, N., Wang, Z., Chen, J., Chen, H., Wang, D., Zhou, L., Wei, K., Zhang, H., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6024 · Cited by 33
CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer
Jiang, Q., Chen, Z., Meng, F., Zhang, H., Chen, H., Xue, J., Shen, X., Liu, T., Dong, L., Zhang, S., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87635 · Cited by 32
de Smith, A. J., Walsh, K. M., Francis, S. S., Zhang, C., Hansen, H. M., Smirnov, I. V., Morimoto, L. M., Whitehead, T. P., Kang, A. Y., Shao, X., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31622 · Cited by 33
Bresnick, E. H., & Johnson, K. D. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000378 · Cited by 32
Topography of transcriptionally active chromatin in glioblastoma
Xu, L., Chen, Y., Huang, Y., Sandanaraj, E., Yu, J. S., Lin, R. Y., Dakle, P., Ke, X., Chong, Y. K., Koh, L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd4676 · Cited by 35
Metadata
- Authors
- Mansour, M. R., Abraham, B. J., Anders, L., Berezovskaya, A., Gutierrez, A., Durbin, A. D., Etchin, J., Lawton, L., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Sanda, T., Young, R. A., & Look, A. T.
- Affiliations
- Harvard University (US)
- Whitehead Institute for Biomedical Research (US)
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
- Boston Children's Hospital (US)
- University of California, San Francisco (US)
- Children's Hospital Colorado (US)
- National University of Singapore (SG)
- Corresponding author
- Abraham, Brian J.
- Anders, Lars
- Young, Richard A.
- Look, A. Thomas
- ORCID
- Venue
- Science
- Published
- 2014-12-12
- Volume
- 346
- Issue
- 6215
- Pages
- 1373-1377
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4720521
- OpenAlex
- W2082414039
- Cited by
- 801
- References
- 46
- Citations by year
- 2026: 32 · 2025: 49 · 2024: 61 · 2023: 77 · 2022: 84 · 2021: 85 · 2020: 80 · 2019: 62 · 2018: 65 · 2017: 77 · 2016: 76 · 2015: 49 · 2014: 4
- FWCI
- 28.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- PMC
- Funders
- National Human Genome Research Institute (R01HG002668)
- National Cancer Institute (R21CA167124, CA114766, CA30969, R01CA176746, CA‐98413, U10CA098413, U24CA114766, U10CA030969, P01CA068484, CA 29139, R01CA120215, 5P01CA68484, U10CA029139, U10CA098543, P01CA109901, CA167124, CA120215, CA-98543, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- super-enhancers, T-cell acute lymphoblastic leukemia, MYB transcription factors, somatic mutations, H3K27 acetylation, CBP, RUNX1, GATA3, transcriptional regulation, oncogene expression
- MeSH terms
- T-Cell Acute Lymphocytic Leukemia Protein 1, Acetylation, Base Sequence, Binding Sites, Enhancer Elements, Genetic, Histones, Humans, Molecular Sequence Data, Mutation, Oncogenes, Proto-Oncogene Proteins, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-myb, DNA, Intergenic, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Basic Helix-Loop-Helix Transcription Factors, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, INDEL Mutation, Protein Interaction Domains and Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
